ONCAlert | Upfront Therapy for mRCC
Videos  >  

Expert Discusses Treatment Options for HCC According to Disease Stage

Josep M. Llovet, MD, PhD
Published Online:3:21 PM, Thu February 14, 2019

Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program and professor of medicine at the Icahn School of Medicine, Mount Sinai Hospital, discusses the available treatment options for patients with hepatocellular carcinoma (HCC).

The standard of care for early-stage HCC, which makes up about 40% of patients, is resection, transplant, or local ablation, says Llovet. For intermediate-stage disease, the standard is chemoembolization. For the 40% of patients with advanced disease, frontline sorafenib (Nexavar) has been the standard of care for almost 12 years.

Over the last few years, there have been 6 additions to the armamentarium for advanced HCC, including lenvatinib (Lenvima), regorafenib (Stivarga), cabozantinib (Cabometyx), and ramucirumab (Cyramza). Llovet says nivolumab (Opdivo) and pembrolizumab (Keytruda) were also approved by the FDA based on phase II data.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.